Annatto extract compositions including tocotrienols and tocopherols and methods of use
Compositions and methods of use of annatto extracts [350-450 Dalton molecular weight fraction] including tocotrienols and tocopherols with an appropriate spectrum. This spectrum includes but not limited to low alpha tocopherol, high delta- and gamma-tocols, and mixtures with other extracts [350-450 Dalton molecular weight fraction] like palm and rice and/or nutrients.
1. A composition comprising a mixture of an annatto extract with tocotrienol and a natural extract with tocotrienol, wherein the tocotrienol in the mixture has a ratio of delta-tocotrienol to gamma-tocotrienol from 1:25 to 25:1.
2. The composition of claim 1 , wherein tocopherol is from less than 50% to less than 1%.
3. The composition of claim 1 , where the natural extract is selected from the group consisting of soy, corn, rice bran, palm, olive, wheat germ, oat bran, sunflower seed, cottonseed, cranberry seed, and litchi seed.
4. The composition of claim 2 , wherein the tocopherol is alpha-T1.
5. The composition of claim 1 , wherein more than 50% of the tocotrienol is delta-T3 and gamma-T3.
6. The composition of claim 1 , wherein more than 50% of the tocotrienol is delta-T3.
7. The composition of claim 1 , wherein the composition is tocopherol-free.
8. The composition of claim 1 , wherein the tocotrienol is a C5 unsubstituted tocotrienol and the composition comprises more than 60% C5 unsubstituted tocotrienol, and less than 15% tocopherol.
9. The composition of claim 1 , wherein the tocotrienol activates PPARs.
10. The composition of claim 9 , where the tocotrienol further down regulates SREBP transcription factors.
11. The composition of claim 1 , where the tocotrienol decreases triglyceride concentration in blood.
12. The composition of claim 11 , where the decrease in the triglyceride concentration in the blood has an effect selected from the group consisting of reversal of insulin resistance, metabolic syndrome, prediabetes, diabetes and diabetes-related cardiovascular disease.
13. The composition of claim 1 , where a tocotrienol treats a malady affecting the central nervous system.
14. The composition of claim 13 , where a tocotrienol treats a malady affecting the central nervous system, and the malady is selected from the group consisting of dysautonomia, acute nerve damage, neural degenerative genetic disease, acute brain damage, brain trauma, chronic nerve damage, neural toxicity, chronic brain damage, Alzheimer's, Parkinson's, and Huntington's.
15. The composition of claim 1 , where the tocotrienol has a beneficial effect selected from the group consisting of lowers CRP, protects against inflammation, lowers cholesterol, decreases cardiovascular risk index, decreases metabolic risk index, decreases chemotactic bioactive materials, reduces osteoporosis, increases bone mineralization, enhances immune system, lowers lipids, and reverses insulin resistance.